EPS100Momentum's  Instablog

Send Message
Author has a degree in Engineering and is an avid investor in the market. Experience in industrial materials and structures. In college studied atomic & nuclear physics as well as material engineering. Eastern European
My blog:
EPS100Momentum's Instablog at SeekingAlpha
  • $12 Billion US market drug of CLDA approved by FDA , will be worth even more Multi-Billions Worldwide. 0 comments
    Jan 24, 2011 9:55 AM | about stocks: CLDA, DNDN, MRK, PFE, LLY, BIIB

    $CLDA biotech ready to turn into EPS Momentum type stock with FDA approval. http://tinyurl.com/6zkn8cp

    Clinical Data (CLDA 23.80) initiated with a Mkt Outperform at Rodman & Renshaw; tgt $46. Firm believes that Viibryd's unique safety profile holds a substantial commercial potential and that Clinical Data may be an attractive acquisition target for large pharmaceutical companies. Firm estimates that Viibryd may reach a blockbuster status of $1B in annual sales within four years of launch, which we believe is reasonable based on the reported revenue for other recently launched antidepressants. Additionally, firm sees potential upside to their target price from a more successful launch, potential label expansion into other psychiatric indications for Viibryd, as well as the clinical and commercial success of Stedivaze, a Phase 3 drug that they did not include in the current valuation.

    $CLDA barely trading +3/shr higher than Oct. high $20 Upside is huge there was no prior FDA approval run here, actually it was a sellof prior to the FDA news. Shorts were expecting FDA rejection and caused shares to selloff from $20 to low teens.


    According to articles I have been reading: Viibryd will have $1+ Billion potential sales in USA alone. Once approved in other countries (other nations usually follow US FDA path) The potential sales will be in the multi billions per year worldwide. But for now the drug is entering a $12 billion market in the USA.

Back To EPS100Momentum's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.